Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C(=O)CCCC#C
InChI
InChIKey=ZHXUEUKVDMWSKV-UHFFFAOYSA-N
InChI=1S/C20H28O2/c1-8-9-10-11-17(21)14-12-15(19(2,3)4)18(22)16(13-14)20(5,6)7/h1,12-13,22H,9-11H2,2-7H3
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tebufelone (formerly NE-11740) is a member of the di-tert-butyl-phenol anti-inflammatory agents. Tebufelone is a dual cyclooxygenase (CO)/5-lipoxygenase (LO) inhibitor that has potent analgesic, antipyretic, and anti-inflammatory effects. This drug was studied for the treatment of rheumatic disorders; however, this study was discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2069096
Subjects received a single peroral dose of placebo, 650 mg aspirin (ASA), or tebufelone at doses of 25, 50, 100, or 200 mg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:14 GMT 2023
by
admin
on
Fri Dec 15 15:31:14 GMT 2023
|
Record UNII |
O048K9ZFHO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
O048K9ZFHO
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
SUB10854MIG
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
6601
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
DTXSID10149818
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
112018-00-5
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
60542
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
C152522
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
100000082455
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
AA-25
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL13878
Created by
admin on Fri Dec 15 15:31:14 GMT 2023 , Edited by admin on Fri Dec 15 15:31:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |